TrialBlood cancer journal2021

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).

Andrew H Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.